Sheppard Mullin advised Signet Healthcare Partners in its recent growth investment in NorthX Biologics, a Swedish biopharmaceutical Contract Development and Manufacturing Organization (CDMO). The strategic partnership will enable NorthX Biologics to accelerate its expansion plans, including enhancing facilities, broadening service lines and extending U.S. commercial reach.
Signet Healthcare Partners is a leading provider of growth capital to innovative healthcare companies with a focus on the pharmaceutical and medical device sectors. With over 25 years of experience, Signet has raised cumulative capital commitments exceeding $600 million and invested in over 60 companies. The firm works closely with its portfolio companies to drive value and accelerate growth.
The Sheppard Mullin deal team was led by partner Shon Glusky.
Click here to read the press release.